Subsequently, EZH2 interacts with NF-κB to form the EZH2–p-p65-Ser536 complex, which binds to the IL-6 promoter and leads to the accumulation of immunosuppressive myeloid-derived suppressor cells (MDSCs), providing a tumor immunosuppressive microenvironment and inducing drug resistance [41]. Here, EZH2 is linked to neoplasm.